News

Zepbound beats Wegovy for weight loss in trial of blockbuster drugs
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Fierce Pharma10h
Consumers remain averse to out-of-pocket GLP-1 costs: KPMG
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...
Barchart on MSN2h
This Pharma Stock Is Still a ‘Strong Buy’ Despite Trump’s Plans to Lower Drug Prices
While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...
2 Minute Medicine1h
Eli Lilly Takes Legal Action Against Telehealth Startups
Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...
Zacks Investment Research on MSN2h
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
STAT1h
Califf blasts RFK Jr. for downplaying vaccine comments
Meanwhile, at STAT’s Breakthrough Summit West in San Francisco, former FDA Commissioner Robert Califf criticized RFK Jr.’s ...
pharmaphorum14h
AstraZeneca to work with Lilly on Alzheimer's drug
Lilly and AZ have a rival in the BACE field – Merck's MK-8931 is currently in a phase 2/3 study treating patients with mild to moderate Alzheimer's. BACE offers hope ...